Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab

Am J Hematol. 2019 Jan;94(1):E7-E8. doi: 10.1002/ajh.25317. Epub 2018 Nov 25.

Authors

Firas El Chaer^{1

2}, Omer M Ali¹, Edward A Sausville^{1

2}, Jennie Y Law^{1

2}, Seung Tae Lee^{1

2}, Vu H Duong^{1

2}, Maria R Baer¹, Rima Koka³, Zeba N Singh³, Jerry Wong⁴, Jean A Yared^{1

2}, Elizabeth A Griffiths⁵, Ashkan Emadi^{1

2}

Affiliations

¹ Departments of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
² University of Maryland Greenebaum Comprehensive Cancer Center Baltimore, Baltimore, Maryland.
³ Departments of Pathology, University of Maryland School of Medicine, Baltimore, Maryland.
⁴ Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
⁵ Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

PMID: 30328137
DOI: 10.1002/ajh.25317

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Bispecific / therapeutic use*
Antigens, CD19 / analysis*
Antigens, CD19 / immunology
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cell Lineage
Combined Modality Therapy
Cytarabine / administration & dosage
Dasatinib / administration & dosage
Daunorubicin / administration & dosage
Drug Substitution
Female
Hematopoietic Stem Cell Transplantation
Humans
Immunophenotyping
Leukemia, Biphenotypic, Acute / drug therapy*
Leukemia, Biphenotypic, Acute / pathology
Leukemia, Biphenotypic, Acute / therapy
Male
Middle Aged
Molecular Targeted Therapy*
Neoplasm, Residual
Neoplastic Stem Cells / chemistry
Neoplastic Stem Cells / immunology
Neoplastic Stem Cells / pathology
Remission Induction

Substances

Antibodies, Bispecific
Antigens, CD19
Antineoplastic Agents, Immunological
CD19 molecule, human
Cytarabine
blinatumomab
Dasatinib
Daunorubicin